BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2018

Mar 8, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2018-03-06

Reporting Person: Babu Yarlagadda S (Senior VP - Drug Discovery)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-06	Common Stock	M	20622	$3.26	Acquired	120618	Direct
2018-03-06	Common Stock	F	15223	$5.18	Disposed	105395	Direct
2018-03-06	Common Stock	M	9378	$3.26	Acquired	114773	Direct
2018-03-06	Common Stock	F	5902	$5.18	Disposed	108871	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-06	Non-Qualified Stock Option	$3.26	M	20622	Disposed	2018-03-14	Common Stock (20622)	Direct
2018-03-06	Emp. Stock Option (Right to Buy)	$3.26	M	9378	Disposed	2018-03-14	Common Stock (9378)	Direct

Footnotes

F1: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.

F2: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.